VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

Viking Therapeutics (VKTX) has initiated Phase III VANQUISH studies for its subcutaneous obesity drug VK2735, targeting obese adults with or without type II diabetes, following promising Phase II results. While VK2735, a dual GLP-1/GIP agonist, demonstrates significant weight reduction potential and an oral formulation is also in development, VKTX operates within an intensely competitive and rapidly expanding obesity market, projected to reach $100 billion by 2030, which is currently dominated by Eli Lilly and Novo Nordisk, with other major pharmaceutical companies like Amgen also making significant advancements. Despite the drug's promise, VKTX shares have declined 32.6% year-to-date, significantly underperforming the industry, and the stock carries a Zacks Rank #4 (Sell), reflecting market skepticism amidst the fierce competitive landscape.

Analysis

Viking Therapeutics (VKTX) has achieved a significant clinical milestone by initiating its Phase 3 VANQUISH program for the subcutaneous obesity drug candidate, VK2735. This progression is supported by strong Phase 2 VENTURE study results, where the drug achieved a statistically significant mean body weight reduction of up to 14.7%. The candidate's potential is enhanced by its dual GLP-1/GIP receptor agonist mechanism, which may offer superior efficacy, and the development of an oral version with Phase 2 data anticipated in the second half of 2025. However, this clinical promise is set against a challenging market reality. The company's stock has underperformed its industry peers significantly, declining 32.6% year-to-date compared to the industry's 2.7% decrease. Furthermore, VKTX faces intense competition in a market projected to reach $100 billion, currently dominated by Eli Lilly and Novo Nordisk, with other major players like Amgen also advancing their own candidates into late-stage trials. The explicit Zacks Rank #4 (Sell) signals substantial market skepticism about VKTX's ability to successfully commercialize its asset against these formidable, well-capitalized competitors.

Key Decisions for Investors

• Investors should weigh the significant clinical potential of VK2735, evidenced by its successful Phase 2 outcomes and advancement to Phase 3, against the extreme execution and commercialization risk posed by entrenched competitors like Eli Lilly, Novo Nordisk, and Amgen.
• The upcoming Phase 2 data for the oral formulation of VK2735, expected in H2 2025, should be monitored as a critical catalyst, as a successful oral agent could materially differentiate Viking from current market leaders.
• Given the stock's 32.6% year-to-date decline and the explicit Zacks #4 (Sell) rating, any long position should be considered highly speculative and sized appropriately, as the path to market share involves overcoming substantial competitive and financial hurdles.